News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform

SEATTLE, December 02, 2016 — Impel NeuroPharma, Inc., a Seattle based clinical stage biotechnology company developing first-in-class intranasal drug treatments for central nervous (CNS) disorders today announced that it has closed a Series C funding round in an amount up…